H. Robert Superko/a4m.com
Aug 11, 2025, 06:08
New Data From WHS and ASPREE: Aspirin Heart Disease Prevention Conundrum
Maxima Mendez, Cardiologist, CEO of Cli-Lipid and the Cardiovascular Lipid Club, shared a post on X:
“New data from WHS and ASPREE:
Aspirin and Lpa
•LPA+ genotype → higher CVD risk, aspirin reduced events significantly (NNT: 38–34)
•LPA– genotype → normal CVD risk, bleeding risk outweighs benefit (NNT: 833–250)”
Read the full article here.
Article: The aspirin heart disease prevention conundrum
Authors: H. Robert Superko, John Sninsky, Brenda Garrett․
Stay updated with Hemostasis Today.
-
Jul 9, 2026, 12:41Thomas Palmer-Dench: Hexokinase Controls Platelet Activation and Hemostasis
-
Jul 9, 2026, 12:19Paschalis Evangelidis: Join Our Special Issue on Thrombosis and Vascular Disorders
-
Jul 9, 2026, 12:16Fernanda Betti Solano: Could Iron Deficiency Be Affecting Your Sleep?
-
Jul 9, 2026, 12:08Andreas Calatzis: What is the Rationale for Collagen-Induced Platelet Aggregation Testing?
-
Jul 9, 2026, 11:54Deepak Pradhan։ Can Withaferin-A Help Combat Drug-Resistant Malaria?
-
Jul 9, 2026, 11:26Peter Zhang: Is Canada Ready for the Gene Therapy Era?
-
Jul 9, 2026, 09:35Pradeebha Muthukumar: Do You Know the Signs of Anemia?
-
Jul 9, 2026, 09:24Maryam Majid: Machine Learning for Anemia Risk Prediction
-
Jul 9, 2026, 08:46Jordan Agay: Folate Deficiency in Patients Receiving PARP Inhibitors